key: cord-0789196-nc2wqvrq
authors: López‐Valle, Alba; Falkenhain‐López, Daniel; Arranz, Celia R.
title: Cutaneous reaction to BNT162b2 mRNA COVID‐19 vaccine
date: 2021-04-14
journal: Int J Dermatol
DOI: 10.1111/ijd.15575
sha: 214a10a9f60dd7c557ad7f351f34d87cafcfb6c8
doc_id: 789196
cord_uid: nc2wqvrq

nan

The patient had no history of hypersensitivity reactions to previous vaccines. She had not experienced COVID-19 symptoms. She was tested with nasopharyngeal RT-PCR four times from April to December (because of risk contacts) with negative results. COVID-19 serologies were performed in April, June, and December, with negative results.

In comparison with conventional vaccines, mRNA vaccines have the potential for rapid, scalable manufacturing, which makes them useful for potentially pandemic infectious diseases. 1 To date, only two mRNA vaccines for the prevention of infectious diseases are approved for commercialization:

BNT162b2 and mRNA-1273. Both are lipid-nanoparticle-encapsulated RNA encoding SARS-CoV-2 spike protein and are administered by injection into the deltoid muscle in a two-dose regimen. 2, 3 In the clinical trial of BNT162b2 vaccine, 2 the percentage of local reactions in patients between 16 and 55 years, 1-7 days after the first dose, was: 78% pain, 6% redness, and 6%

inflammation. Most reactions were mild or moderate and 

mRNA vaccinesa new era in vaccinology

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Immunemediated adverse reactions to vaccines

Funding source: None. doi: 10.1111/ijd.15575